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Abstract Activated protein C (APC), an endogenous
protein, inhibits inflammation and thrombosis and inter-
rupts the coagulation cascade. Here, we investigated the
effect of human recombinant APC on the development of
neointimal hyperplasia in porcine coronary arteries. Yukon
Choice bare metal stents were coated with 2.6 lg APC/
mm2. Under general anesthesia, APC-coated and bare
stents were implanted in the left anterior descending and
circumflex coronary arteries of 10 domestic pigs. During
the 4-week follow-up, animals were treated with dual
antiplatelet therapy and neointimal hyperplasia was eval-
uated via histology. Scanning electron microscopy indi-
cated successful but unequal coating of stents with APC;
nearly complete drug release occurred within 4 h. Enzyme-
linked immunosorbent assay revealed that intracoronary
stent implantation rapidly increased the levels of monocyte
chemoattractant protein-1, an effect that was inhibited by
APC release from the coated stent. Fibrin deposition and
adventitial inflammation were significantly decreased
1 month after implanting APC-coated stents versus bare
stents, paralleled by significantly smaller neointimal area
(0.98 ± 0.92 vs. 1.44 ± 0.91 mm2, P = 0.028), higher
lumen area (3.47 ± 0.94 vs. 3.06 ± 0.91 mm2,
P = 0.046), and lower stenosis area (22.2 ± 21.2 % vs.
32.1 ± 20.1 %, P = 0.034). Endothelialization was com-
plete with APC-coated but not bare (90 %) stents. P-se-
lectin immunostaining revealed significantly fewer
activated endothelial cells in the neointima in the APC
group (4.6 ± 1.9 vs. 11.6 ± 4.1 %, P\ 0.001). Thus,
short exposure of coronary arteries to APC reduced
inflammatory responses, neointimal proliferation, and in-
stent restenosis, offering a promising therapy to improve
clinical outcomes of coronary stenting. However, coating
stents with APC for prolonged, controlled drug release
remains technically challenging.
1 Introduction
Coated stents have been shown to overcome the high in-
stent restenosis rate of bare metal stents (BMSs). Several
candidate drugs for stent coatings were tested: molecules in
the limus group (e.g. sirolimus, everolimus, tacrolimus,
biolimus), molecules in the taxol group (e.g. taxane,
paclitaxel), estradiol, statin, glitazon, and combinations of
substances (e.g. rapamycin with estradiol) [1]. However,
most coating materials (e.g. cytostatics, antiproliferative
drugs, or the drug-carrying polymer itself) may exert toxic
effects on the arterial wall, causing vessel aneurysms and
focal necrosis with accompanying severe inflammatory
reactions [2].
Activated protein C (APC) is an endogenous protein that
inhibits inflammation, apoptosis, and thrombosis, promotes
fibrinolysis, and is an important modulator of the coagu-
lation and inflammation systems [3–5]. APC is converted
from its inactive precursor, protein C, by thrombin coupled
to thrombomodulin [5]. Importantly, APC acts against
local cell proliferation and thrombosis, factors known to
contribute to the progression of coronary artery disease and
the development of restenosis after percutaneous coronary
intervention or stent thrombosis via its anti-inflammatory,
antithrombotic, fibrinolytic, and antiapoptotic functions.
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APC inhibits monocyte production of several inflam-
matory cytokines (tumor necrosis factor alpha and inter-
leukins 1, 6, and 8) and limits the migration of monocytes
and neutrophils to injured endothelium by binding selectins
[4, 5]. APC also interrupts the coagulation cascade by
inhibiting the generation of thrombin via inactivating fac-
tors Va and VIIIa [3, 5] and by reducing intravascular fibrin
accumulation [5–10]. Further, APC promotes fibrinolysis
by attenuating the production of thrombin, thereby limiting
the activation of thrombin-activated fibrinolysis inhibitor
[8], and increases the fibrinolytic response indirectly by
inhibiting plasminogen activator inhibitor-1 [11]. These
factors also play a role in local acute and chronic vascular
inflammation and thrombosis after percutaneous coronary
intervention.
Based on these anti-inflammatory, antithrombotic, and
fibrinolytic properties, APC may constitute an optimal
stent-coating substance for the prevention of in-stent
restenosis and stent thrombosis. Initial clinical results
indicated that human recombinant APC (hrAPC, dro-
trecogin alfa (Xigris), Eli Lilly, Indianapolis, IN, USA)
reduced mortality in sepsis [12–14], including in patients
with severe sepsis and septic shock. However, Xigris was
withdrawn from the market (http://www.fda.gov/Drugs/
DrugSafety/ucm277114.htm) after large randomized stud-
ies failed to detect survival benefits.
Based on the expected antithrombotic effect of APC,
rabbit iliac arteries were treated with APC-loaded stents;
this treatment inhibited platelet deposition on stent wires,
with indirect evidence of APC elution [15]. In the current
investigation, we sought to explore the potential benefits of
hrAPC in a porcine pre-clinical stenting model, to inves-
tigate the safety and efficacy of hrAPC-coated stents, and
to determine the effects of hrAPC-coated stents on the
development of neointimal hyperplasia, local endothelial-
ization, and the inhibition of endothelial-cell activation.
We chose Xigris as the coating substance because addi-
tional components of this drug could inhibit the immediate
proteolytic inactivation of APC and promote the retention
of hrAPC on the stent surface.
2 Materials and methods
2.1 Coating of stents with hrAPC
Sixteen Yukon Choice BMSs (Translumina GmbH,
Hechingen, Germany) with surface micropores that
allowed polymer-free drug loading were coated with
solution containing 300 lg hrAPC in sterile water (as
recommended by the manufacturer) using the Translumina
Stent Coating System (T-SCM 2003, Translumina). After
coating, the stent was left in the cartridge to ensure
attachment of the drug to the stent surface and to allow the
coating to dry. All necessary care was taken to maintain
sterility.
2.2 In vitro drug-release kinetics
After coating, five stents were removed from the sterile
plastic bag, dilated with the stent balloon, and cut from the
catheter. Dilated hrAPC-coated stents were placed in an
artificial vessel-system filled with 2 mL 37 C pre-warmed
Ringer’s solution. The artificial vessel system was fixed
within a shaking device that was also pre-warmed to 37 C.
At certain time points, Ringer’s solution was withdrawn
and the artificial vessel system was refilled with new
warmed Ringer’s solution. Extinction of Ringer’s solution
was measured and compared to that of reference Ringer’s
solution. To determine hrAPC activity, 0.5 mg/mL of a
chromogenic substrate of APC (Chromogenix S-2366,
DiaPharma, West Chester Township, OH, USA) was mixed
with 0.5 mg/mL pure APC (Haematologic Technologies
Inc., Essex Junction, VT, USA) or with 10 mg/mL hrAPC
(Xigris) dissolved in distillated water. Absorbance was
measured with a photometer.
2.3 Animal preparation
Ten male domestic pigs (weight 20–25 kg) were fasted
overnight and then sedated with 12 mg/kg ketamine
hydrochloride, 1 mg/kg xylazine, and 0.04 mg/kg atropine.
Anesthesia was deepened with isoflurane and O2 via a
mask. Intratracheal intubation was then performed to
maintain anesthesia with 1.5–2.5 vol% isoflurane, 1.6–1.8
vol% O2, and 0.5 vol% N2O.
Arteriotomy of the right femoral artery was performed
under sterile conditions. After administration of 100 IU/kg
unfractionated heparin, a 6F introduction sheath was
inserted. Heart rate, arterial blood pressure, electrocardio-
graphy, and temperature were monitored and arterial blood
was sampled to control blood gases and acid–base balance
throughout the procedure. Left and right coronary
angiographies were performed using regular contrast
medium (Ultravist, Bayer, Leverkusen, Germany).
Stents (BMSs and coated stents, 15 mm in length, 3 or
3.5 mm in diameter) were implanted either in the left
anterior descending or left circumflex coronary arteries.
Stent sizes and implantation pressures (8–12 atm, 30 s
inflation) were chosen to achieve a stent:artery ratio of
1.1:1. A single stent was implanted in each artery. Pigs
were randomized to receive either BMS or hrAPC-coated
stents (up to two stents per animal).
After repeat coronary angiography, the guiding catheter
and the introducer sheath were removed, the arteriotomy
was ligated, and the skin was closed in two layers. Animals
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were allowed to recover from anesthesia and received
metamizol for pain relief.
One day before coronary stent implantation, a loading
dose of 250 mg aspirin and 300 mg clopidogrel was
administered per os. During the 1-month follow-up, a daily
dose of 100 mg aspirin and 75 mg clopidogrel was
administered per os.
Animal investigations were carried out in accordance
with the ‘‘Position of the American Heart Association on
Research Animal Use,’’ as adopted by the AHA on
November 11, 1984. The study was approved by the Ethics
Committee on Animal Experimentation at the University of
Kaposvar, Hungary.
2.4 Control angiography after 4 weeks
At the 4-week follow-up, control angiography was per-
formed under general anesthesia. After euthanasia with
saturated potassium chloride, the heart was explanted and
examined for evidence of infarction or fibrosis, especially
in the location and perivascular region of the stents.
Coronary arteries were flushed with *300 mL saline
before pressure fixation in situ (100–110 mmHg) with
500 mL 4 % buffered formaldehyde. Coronary arteries
were then dissected from the epicardial surface and fixed in
2 % buffered formalin for 24 h. Arteries with stents were
embedded in Technovit 9100 (Heraeus Kulzer, Wehrheim,
Germany). Hearts were then sectioned transaxially (along
the short axis) at a minimum of 1-cm intervals. These
sections underwent gross examination for evidence of
myocardial infarction.
Serial peripheral venous blood samples were taken from
the pigs before stenting as well as at 5 min, 10 min,
20 min, 30 min, and 1 day after stenting for measurements
of APC (MyBioSource Inc., San Diego, CA, USA) and
monocyte chemoattractant protein-1 (MCP-1; Abcam,
Cambridge, UK). Samples obtained 10 min after implan-
tation, at 1 week, and at 4 weeks were used to determine
counts of eosinophils, platelets, and red and white blood
cells.
2.5 Quantitative assessment of coronary
angiography
Pre-stent, post-stent, and follow-up quantitative angio-
graphic parameters were measured with a computer-as-
sisted quantitative coronary arteriographic edge-detection
algorithm (ACOMPC, Siemens, Germany) by an investi-
gator blinded to the stent type. In order to minimize vari-
ation in cardiac cycle-dependent dimensions, end-diastolic
frames were chosen for the assessment of pre-, post-stent,
and follow-up minimal lumen diameter, reference diame-
ter, and percent diameter stenosis. Late lumen loss was
calculated as the difference between post-stent and follow-
up minimal lumen diameter.
2.6 Histopathology and histomorphometry
of stented arteries
Histological analyses were performed by an experienced
investigator blinded to stent type [16, 17]. Five sections of
the stented arteries were analyzed: the proximal reference
segment (stent-free artery tissue within 10 mm from the
stent edge); artery tissue at the proximal stent edge; artery
tissue at the middle portion of the stent (stent body); artery
tissue at the distal stent edge; and the distal reference
segment (stent-free artery tissue within 10 mm from the
stent edge). Arterial segments were stained with hema-
toxylin-eosin to determine the location and extent of injury.
The following histopathological parameters were mea-
sured: injury score, fibrin score, inflammation score,
necrosis and hemorrhage scores, and endothelialization
[16, 17]. Injury score was determined in accordance with
Schwartz et al. [16]. Fibrin score was graded from 0 to 3 to
reflect no fibrin deposition or mild, moderate, or heavy
fibrin deposition involving\10 %, 10–25 %, or[25 % of
the circumference of the vessel, respectively. Inflammation
score was graded as 0 for no inflammation or\25 % struts
with\10 inflammatory cells; 1 for up to 25 % struts with
[10 inflammatory cells; 2 for 25–50 % struts with[10
inflammatory cells; 3 for[50 % struts with[10 inflam-
matory cells; and 4 for two or more struts-associated
granulomatous inflammatory reactions. Necrosis and
hemorrhage were scored as 0 if absent, 1 if mild, 2 if
moderate, or 3 if heavy (if necrotic or hemorrhagic changes
were seen around at least one stent strut). Endothelializa-
tion was evaluated as percent of stent struts covered by
endothelium.
The following four quantitative histomorphometric
parameters of the dilated segment, proximal reference
segment, and distal reference segments were measured:
lumen area; internal elastic-lamina area; external-elastic
lamina area; and maximal neointimal thickness. Calculated
histomorphometric parameters included: neointima area
(difference between internal elastic-lamina and lumen
areas); media area (difference between external-elastic
lamina and internal elastic-lamina areas); percent area
stenosis ((neointimal area/internal elastic - lamina
area) 9 100); remodeling index (external-elastic lamina
area of the stented arterial segment/external-elastic lamina
area of the proximal reference segment); and proximal or
distal edge effects (neointimal area of the proximal or distal
reference segment/neointimal area of the stented segment).
Myocardial sections beneath the stented arteries were
dissected and stained with hematoxylin-eosin and evalu-
ated for cellular infiltration, inflammation, and necrosis.
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2.7 P-selectin immunohistochemistry
Representative coronary-artery sections were stained with
mouse anti-human P-selectin antibody (Genway Biotech,
San Diego, CA, USA), which is known to cross-react with
porcine tissue samples [18]. Sections were stained with
hematoxylin-eosin for general morphology (Olympus
Microscopy, Deutschland GmbH, Hamburg, Germany).
The number of cells positive for P-selectin was calculated
as the percentage of all visible cells.
2.8 Statistical analysis
Continuous parameters are expressed as mean ± standard
deviation. Categorical variables are reported as percent-
ages. Continuous variables were compared with the two-
tailed Student’s t test, while categorical variables were
assessed with the Chi squared test. P values\ 0.05 were
considered significant. Statistical analyses were performed
with SPSS version 17 for Macintosh.
3 Results
3.1 hrAPC coating and in vitro release kinetics
The control mechanism of the coating machine ensured
that no residual drug was retained in the coating box. Each
hrAPC-coated stent had a polymer-free coating of hrAPC
with 2.3–2.6 lg hrAPC/mm2 of stent surface. Exposure to
the chromogenic substrate indicated that the hrAPC coating
was active, but also demonstrated hrAPC inactivation fol-
lowing repeated coating.
The in vitro drug-release curve revealed immediate release
of the drug from the stent, with 50 % release at 30 min and
nearly complete release after 4 h (Fig. 1a–c). Scanningelectron
microscopy showed complete coverage of the stent with
hrAPC. However, the coating was not homogeneous (Fig. 1d),
probablydue to thepresence of pharmaceutical substances used
tomaintain hrAPCas a dry powder.Additionally, run-out of the
coating solution into the inter-strut spaces of the balloon surface
occurred, likely due to incomplete adherence of the coating
substance to the stent struts (Fig. 1e, f).
3.2 APC and MCP-1 levels
APC levels were low prior to implantation, and immedi-
ately increased in pigs that received hrAPC-coated stents
(Fig. 2a). However, 10 min later, APC levels dropped to
baseline levels and remained low in these animals
(Fig. 2a). MCP-1 was absent at baseline but increased
slightly over time in both groups (Fig. 2b). This change
was significant within minutes in animals with BMSs
(Fig. 2b). MCP-1 levels returned to baseline after the first
few minutes in both groups (Fig. 2b).
3.3 Stenting procedural data
No procedural complications or allergic reactions were
observed. Premature death, acute or sub-acute stent throm-
bosis, and concomitant disease were absent during follow-
up. No changes in the numbers of red and white blood cells,
platelets, or eosinophils were detected at any time point.
3.4 Quantitative coronary angiography
Vessel diameters did not differ between stent groups before or
after coronary procedures. At the 1-month follow-up, the
meanminimal lumen diameter of animals with hrAPC-coated
stentswas significantly higher than that of animalswithBMSs
(2.51 ± 0.17 vs. 2.23 ± 0.32 mm, P = 0.033) and the per-
cent area stenosis was smaller (16 ± 0.6 % vs. 26 ± 11 %,
respectively, P = 0.041). Accordingly, late lumen loss was
significantly smaller with hrAPC-coated stents than with
BMSs (0.19 ± 0.17 vs. 0.47 ± 0.32 mm, P = 0.02).
3.5 Histopathology
Histopathology indicated significantly less fibrin deposition
and inflammation in the hrAPC-coated stent group than in
the BMS group (Table 1). All animals had similar injury
scores (Table 1). No granulomatous reaction or giant cells
were documented. Myocardial histopathology uncovered
no abnormalities. Scanning electron microscopy showed
complete endothelialization of all hrAPC-coated stent
struts, in contrast with incomplete endothelialization of
stent struts in one BMS (Fig. 2c).
3.6 Histomorphometric results
Neointimal area, maximal neointimal thickness, and per-
cent area of stenosis were significantly smaller with
hrAPC-coated stents than with BMSs, with consequently
higher lumen area in the hrAPC group (Table 2; Fig. 3).
No vessel remodeling or edge effects were seen.
Immunohistochemistry revealed significantly fewer
P-selectin-positive endothelial cells in animals with
hrAPC-coated stents than in animals with BMSs
(4.6 ± 1.9 % vs. 11.6 ± 4.1 %, P\ 0.001; Fig. 3).
4 Discussion
Our results demonstrate the inhibitory effect of hrAPC-
coated stents on neointimal hyperplasia, fibrin deposi-
tion, and vessel inflammation after implantation, even
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after short exposure of the arterial wall to hrAPC.
Coating stents with hrAPC may therefore be a viable
alternative to coating stents with antiproliferative drugs;
APC is an endogenous protein that does not carry the
risk of systemic or local toxicity. We successfully
coated stents with Xigris, a drug approved by the FDA,
but coating was not homogenous, probably due to
additional pharmaceutical ingredients. However, this
lack of homogeneity did not seem to negatively influ-
ence outcome.
Fig. 1 Coating of polymer-free stents with APC and hrAPC. a,
b Extinction curves of chemical APC (a) and Xigris (panel b;
containing 5 mg/mL hrAPC) mixed with Chromogenix S-2366.
c Rapid release of hrAPC from the stent surface, with nearly
complete release after 4 h. d Scanning electron microscopy of the
hrAPC-coated expanded microporous stent. Note the uneven
distribution of drug on the stent surface. e Scanning electron
microscopy of the coated stent surface showing run-out of the drug
components into the inter-strut space, with crystallization of the
material on the stent-balloon surface. f Scanning electron microscopy
of the stent and balloon surface after stent expansion
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Fig. 2 Time-dependent release
of APC, changes in MCP-1
levels, and endothelialization of
APC-coated stents and BMSs.
a Release of APC immediately
after stenting of porcine
coronary arteries with hrAPC-
coated stents (mean ± SD).
b Differential increase in
circulating MCP-1 levels after
stent deployment (mean ± SD).
c Scanning electron microscopy
shows complete
endothelialization of the
hrAPC-coated stent (left, arrow)
at 1-month follow-up, in
contrast with the BMS (right,
arrows)
Table 1 Histopathologic
results of the Yukon Choice
bare metal stent (Yukon-BMS)
and Yukon-APC (human
recombinant activated protein
C-coated stent)
Yucon-APC (n = 10) Yucon-BMS (n = 10) P value
Injury score 1.35 ± 0.47 1.32 ± 0.52 0.821
Fibrin deposition score 0.55 ± 0.36 1.08 ± 0.32 0.026
Inflammation score 0.64 ± 0.24 0.98 ± 0.21 0.021
Haemorrhagia score 0 0.11 ± 0.08 0.556
Necrosis score 0 0 1
Endothelialization complete 100 % 90 % 0.136
Bold values indicate statistical significance (p\ 0.05)
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4.1 Possible beneficial effects of APC on neointimal
hyperplasia
After stenting-induced vessel injury and compression of the
atherosclerotic plaque, local platelet and fibrin deposition
occur at the injury site, activating platelets and triggering
interactions between leukocytes and platelets [19–21]. The
subsequent inflammatory cascade leads to the discharge of
growth factors and chemokines, which stimulate vascular
smooth muscle cell proliferation and formation of extra-
cellular matrix [22]. By inducing cell signaling, locally
delivered APC may directly modulate this cellular
response, exerting anti-inflammatory, cytoprotective, and
barrier-protective activities [10]. APC has been shown to
downregulate the expression of chemokines, MCP-1, and
the intercellular adhesion molecule 1 family in human
coronary artery endothelial cells [23]. APC was also
effective against ischemia/reperfusion injury via its inhi-
bition of endothelial apoptosis [24]. Use of APC was pre-
viously proposed for the management of microvascular
inflammation [25]. Decreased levels of neointimal hyper-
plasia in animals implanted with hrAPC-coated stents in
the present investigation support the hypothesis that APC,
when coated on a stent, may exert beneficial effects on
stenting-induced local inflammation. The short half-life of
APC and its fast release kinetics are consistent with the
observation that short exposure of the vessel wall to an
antiproliferative substance inhibits neointimal proliferation
[26, 27].
4.2 APC against stent thrombosis
APC has the ability to protect the endothelial barrier [28],
inhibiting the infiltration of inflammatory cells into adja-
cent tissues, interrupting the local inflammation cascade,
and improving endothelial function [29]. These mecha-
nisms may also underlie the quick endothelialization of
stent struts observed here.
APC improves microvascular dysfunction [30] and
decreases the expression and release of tissue factor on the
surface of monocytes and on microparticles derived from
activated platelets and endothelial cells [28, 30]. By
inhibiting thrombin production, APC indirectly reduces
platelet aggregation and degranulation as well as selectin-
mediated adhesion of neutrophils to the endothelium [6]. In
addition, in the early stages of local inflammation, P-se-
lectin mediates the loose contact between leukocytes and
platelets [19]. We detected significantly fewer P-selectin-
expressing cells 1 month after implanting stents coated
with hrAPC versus BMSs, which may reflect the inhibition
of late thrombosis.
4.3 Polymer-free coating of BMSs with hrAPC
The Translumina Stent Coating System enabled us to coat
BMSs without polymer, with the inherent benefit of
avoiding proinflammatory polymer carriers [31]. This
equipment is suitable for coating stents with all ethanol-
soluble substances, including antiproliferatives, angio-
tensin-converting enzyme inhibitors, and hormones. hrAPC
is insoluble in absolute ethanol; therefore, we dissolved it in
distilled water and dried it at room temperature. Although
longer drying decreased the activity of hrAPC on the stent
surface, our in vitro measurements of hrAPC release from
the stent and our observation of increased levels of plasma
APC demonstrate that our strategy resulted in stents coated
with biologically sufficient amounts of hrAPC.
4.4 Economic and clinical considerations of hrAPC-
coated stents
We did not observe allergic reaction to hrAPC in the current
investigation, probably due to the highly similar amino-acid
sequences of porcine APC and hrAPC. Further, like
endogenous APC, hrAPC is irreversibly inactivated by
Table 2 Histomorphometric
results of the Yukon Choice
bare metal stent (Yukon-BMS)
and Yukon-APC (human
recombinant activated protein
C-coated stent)
Yucon-APC (n = 10) Yucon-BMS (n = 10) P value
Lumen area (mm2) 3.58 ± 0.87 3.11 ± 0.97 0.025
Neointimal area (mm2) 1.02 ± 0.92 1.57 ± 0.96 0.013
Internal elastic lamina area (mm2) 4.60 ± 0.44 4.68 ± 0.56 0.269
Media area (mm2) 0.68 ± 0.40 0.63 ± 0.34 0.304
External elastic lamina area (mm2) 5.28 ± 0.61 5.31 ± 0.59 0.424
Maximal neointimal thickness (mm) 0.26 ± 0.12 0.34 ± 0.11 0.012
% Area stenosis (%) 21.7 ± 18.3 33.5 ± 2.6 0.011
Remodeling index 0.88 ± 0.12 0.83 ± 0.15 0.778
Proximal edge effect 0.11 ± 0.07 0.12 ± 0.09 0.833
Distal edge effect 0.09 ± 0.1 0.12 ± 0.06 0.744
Bold values indicate statistical significance (p\ 0.05)
J Mater Sci: Mater Med (2015) 26:241 Page 7 of 10 241
123
endogenous inhibitors in the blood, which form APC-in-
hibitor complexes that have no known biological activity
[32]. hrAPC-coated stents contained very small amounts of
drug, far below the regular dose of a single treatment in
humans. Coating the stent with chemical APC (instead of
Xigris) would likely result in more favorable outcomes, but
coating a stent with a large molecule would require exten-
sive manipulation of a biostable or biodegradable polymeric
matrix in order to ensure constant and regulated drug
release.
Despite the advantages of coating stents with hrAPC, the
high costs of producing hrAPC may limit the widespread
use of hrAPC-coated stents. However, economic studies of
Xigris treatment for severe sepsis supported the cost
effectiveness of this therapy [33]. Preventing restenosis and
stent thrombosis using hrAPC-coated stents may be as cost
effective as other drug-eluting stents. Although Xigris is no
longer commercially available because it was withdrawn
from the market in October 2011, hrAPC may still be an
option as a coating for drug-eluting stents.
Fig. 3 Histology (hematoxylin
and eosin staining) and
immunohistochemistry after
implantation of hrAPC-coated
or BMSs stents. a Histology of
tissue 1 month after
implantation with an hrAPC-
coated stent (left) or a BMS
(right). 29 magnification. Less
neointimal hyperplasia occurred
after implantation of the hrAPC-
coated stent. b Less local
inflammation occurred around
the hrAPC-coated stent strut
(left) than around the BMS strut
(right). 409 magnification.
c Immunohistochemistry of the
porcine coronary artery with
P-selectin antibody 1 month
after implantation. Fewer
P-selectin-positive endothelial
cells (arrows) were detected in
arteries implanted with hrAPC-
coated stents (left) versus
arteries implanted with BMSs
(right)
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5 Conclusion
In conclusion, coronary implantation of hrAPC-coated
stents inhibited stent restenosis, development of neointimal
hyperplasia, and vessel-wall inflammation in comparison
with implantation of BMSs. Due to the antithrombotic, anti-
inflammatory, antiapoptotic, and fibrinolytic properties of
APC, coating stents with hrAPC may be a viable therapeutic
option for preventing stent thrombosis and restenosis.
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